Standout Papers

Oral poly(ADP-ribose) polymerase inhibitor olaparib in p... 1999 2026 2008 2017 1.7k
  1. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial (2010)
    M. William Audeh, James Carmichael et al. The Lancet
  2. PIK3CA is implicated as an oncogene in ovarian cancer (1999)
    Yiling Lu, Wen-Lin Kuo et al. Nature Genetics

Immediate Impact

7 by Nobel laureates 23 from Science/Nature 85 standout
Sub-graph 1 of 16

Citing Papers

PARP and PARG inhibitors in cancer treatment
2020 Standout
Chemotherapy induces enrichment of CD47 + /CD73 + /PDL1 + immune evasive triple-negative breast cancer cells
2018 StandoutNobel
73 intermediate papers

Works of Bethan Powell being referenced

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
2010 Standout
PIK3CA is implicated as an oncogene in ovarian cancer
1999 Standout

Author Peers

Author Last Decade Papers Cites
Bethan Powell 698 652 583 1776 1616 10 2.9k
Craig P. Carden 283 532 406 1094 1140 18 2.1k
Mark Wickens 1116 675 700 1901 2666 13 4.5k
Marja Mergui‐Roelvink 922 692 703 2213 2853 31 3.9k
David S. Boss 927 702 765 2472 3079 24 4.3k
Steven McKinney 363 499 949 1207 1183 28 2.9k
Euan Macpherson 754 1068 390 1291 2273 13 2.9k
Dariush Etemadmoghadam 253 1129 994 1656 1065 23 3.1k
Wen-Lin Kuo 652 258 979 3441 1401 31 4.7k
Raphaël Ceccaldi 579 352 561 3403 1812 22 4.1k
Rachel Brough 475 287 441 2302 2016 39 3.0k

All Works

Loading papers...

Rankless by CCL
2026